94 related articles for article (PubMed ID: 8108114)
1. In vitro transformation of Li-Fraumeni syndrome fibroblasts by SV40 large T antigen mutants.
Maclean K; Rogan EM; Whitaker NJ; Chang AC; Rowe PB; Dalla-Pozza L; Symonds G; Reddel RR
Oncogene; 1994 Mar; 9(3):719-25. PubMed ID: 8108114
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
3. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
4. The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts.
Conzen SD; Cole CN
Oncogene; 1995 Dec; 11(11):2295-302. PubMed ID: 8570180
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?
Williams KJ; Boyle JM; Birch JM; Norton JD; Scott D
Oncogene; 1997 Jan; 14(3):277-82. PubMed ID: 9018113
[TBL] [Abstract][Full Text] [Related]
6. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
7. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
8. Immortalization of BALB/c mouse embryo fibroblasts alters SV40 large T-antigen interactions with the tumor suppressor p53 and results in a reduced SV40 transformation-efficiency.
Tiemann F; Deppert W
Oncogene; 1994 Jul; 9(7):1907-15. PubMed ID: 8208537
[TBL] [Abstract][Full Text] [Related]
9. Immortalization of human cells by mutant and chimeric primate polyomavirus T-antigen genes.
O'Neill FJ; Frisque RJ; Xu X; Hu YX; Carney H
Oncogene; 1995 Mar; 10(6):1131-9. PubMed ID: 7700639
[TBL] [Abstract][Full Text] [Related]
10. Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations.
Barley RD; Enns L; Paterson MC; Mirzayans R
Oncogene; 1998 Aug; 17(5):533-43. PubMed ID: 9704919
[TBL] [Abstract][Full Text] [Related]
11. Converting the JCV T antigen Rb binding domain to that of SV40 does not alter JCV's limited transforming activity but does eliminate viral viability.
Tavis JE; Trowbridge PW; Frisque RJ
Virology; 1994 Mar; 199(2):384-92. PubMed ID: 8122368
[TBL] [Abstract][Full Text] [Related]
12. Transformation and radiosensitivity of human diploid skin fibroblasts transfected with SV40 T-antigen mutants defective in RB and P53 binding domains.
Su LN; Little JB
Int J Radiat Biol; 1992 Oct; 62(4):461-8. PubMed ID: 1357059
[TBL] [Abstract][Full Text] [Related]
13. Identification of SV40 T-antigen mutants that alter T-antigen-induced chromosome damage in human fibroblasts.
Ray FA; Waltman MJ; Lehman JM; Little JB; Nickoloff JA; Kraemer PM
Cytometry; 1998 Apr; 31(4):242-50. PubMed ID: 9551599
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
Capponcelli S; Pedrini E; Cerone MA; Corti V; Fontanesi S; Alessio M; Bachi A; Soddu S; Ribatti D; Picci P; Helman LJ; Cantelli-Forti G; Sangiorgi L
Hum Mutat; 2005 Aug; 26(2):94-103. PubMed ID: 15977174
[TBL] [Abstract][Full Text] [Related]
15. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
16. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells.
Pietruska JR; Kane AB
Cancer Res; 2007 Apr; 67(8):3637-45. PubMed ID: 17440075
[TBL] [Abstract][Full Text] [Related]
17. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
18. Activities of SV40 T antigen necessary for the induction of tetraploid DNA content in permissive CV-1 cells.
Perry MB; Lehman JM
Cytometry; 1998 Apr; 31(4):251-9. PubMed ID: 9551600
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SV40 large T antigen induced apoptosis by small T antigen.
Kolzau T; Hansen RS; Zahra D; Reddel RR; Braithwaite AW
Oncogene; 1999 Sep; 18(40):5598-603. PubMed ID: 10523837
[TBL] [Abstract][Full Text] [Related]
20. Mutation of p53 is not a prerequisite for immortalization of human fibroblasts by SV40 T antigen.
Moorwood K; Price TN; Mayne LV
Exp Cell Res; 1996 Mar; 223(2):308-13. PubMed ID: 8601408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
